FIELD: medicine.
SUBSTANCE: group of inventions relates to a combination for preventing or treating metabolic syndrome, comprising (1) a conjugate containing a peptide with glucagon receptor activity and a biocompatible substance which is an immunoglobulin Fc region, and (2) a compound or substance with therapeutic activity against metabolic syndrome, selected from the group consisting of sitagliptin, empagliflozin, liraglutide, semaglutide and dulaglutide, wherein said combination comprises a conjugate comprising a peptide with activity on a glucagon receptor and a biocompatible substance which is an immunoglobulin Fc region, and a compound or substance with therapeutic activity against metabolic syndrome in amount of 0.01% to 99% by weight, and wherein said peptide comprises an amino acid sequence having SEQ ID NO: 37 also relates to a kit for preventing or treating metabolic syndrome, comprising: (1) a conjugate comprising a peptide with glucagon receptor activity and a biocompatible substance which is an immunoglobulin Fc region; and (2) a compound or substance with therapeutic activity against metabolic syndrome, selected from the group consisting of sitagliptin, empagliflozin, liraglutide, semaglutide and dulaglutide, wherein said combination comprises a conjugate comprising a peptide with activity on a glucagon receptor and a biocompatible substance which is an immunoglobulin Fc region, and a compound or substance with therapeutic activity against metabolic syndrome in amount of 0.01% to 99% by weight, and wherein said peptide comprises an amino acid sequence having SEQ ID NO: 37.
EFFECT: present inventions provide a synergetic effect due to a combination of specific substances in a combination.
11 cl, 9 dwg, 1 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION CONTAINING INSULIN AND GLUCAGON | 2019 |
|
RU2823246C2 |
| THERAPEUTIC USE OF LONG-ACTING TRIPLE AGONIST CONJUGATE HAVING ACTIVITIES ON ALL GLUCAGON/GLP-1/GIP RECEPTORS FOR TREATING LUNG DISEASE | 2020 |
|
RU2829342C1 |
| COMPOSITION FOR TREATING HYPERLIPIDEMIA CONTAINING AN OXYNTOMODULIN DERIVATIVE | 2013 |
|
RU2768853C1 |
| LIQUID COMPOSITION | 2021 |
|
RU2838973C1 |
| CONJUGATE CONTAINING OXINTOMODULIN AND IMMUNOGLOBULIN FRAGMENT, AND ITS APPLICATION | 2012 |
|
RU2733544C2 |
| CONJUGATE OF LONG-ACTING PHYSIOLOGICALLY ACTIVE SUBSTANCE AND ITS USE | 2018 |
|
RU2773823C2 |
| NOVEL OXYNTOMODULIN DERIVATIVES AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM FOR TREATING OBESITY | 2012 |
|
RU2739209C2 |
| INSULIN ANALOGUE COMPLEX WITH REDUCED AFFINITY TO INSULIN RECEPTOR AND ITS USE | 2018 |
|
RU2779462C2 |
| IGG4 Fc FRAGMENT CONTAINING A MODIFIED HINGE REGION | 2014 |
|
RU2800558C1 |
| ANTIBODIES AGAINST TIGIT AND APPLICATION THEREOF | 2019 |
|
RU2750705C1 |
